关于三生制药集团 三生制药集团是一家集研发、生产和销售为一体的生物制药领军企业，致力于以高品质的药品提高患者生存质量，为人类健康造福。目前，集团拥有80余项国家发明专利授权，30余种上市产品，覆盖肿瘤、自身免疫、肾病、代谢及皮肤科等治疗领域。集团拥有抗体药物国家工程研究中心以及生物药和化药双平台的4大研发中心，共有25种在研产品，其中16种作为国家一类新药正在研发，并拥有符合GMP标准的6大生产基地。未来，三生制药集团将继续秉持“珍爱生命、关注生存、创造生活”的理念，全力打造全球领先的中国生物制药企业。 About 3S Pharmaceutical Group 3S Pharmaceutical Group is a leading bio-pharmaceutical company integrating R&D, production and sales, with a focus on improving the life quality of patients with high-quality medicines to benefit human health. At present, the Group owns more than 80 national invention patents and has launched more than 30 kinds of products into the market, covering several treatment fields, among others, cancer, autoimmune, kidney disease, metabolism and dermatology. The Group owns 4 R&D centers of the National Engineering Research Center of Antibody Medicine and dual platforms for biopharmaceutical and chemical medicine. There are 25 kinds of products under R&D, 16 kinds of them are under R&D as the national first-class new drugs. The Group also owns 6 production bases complying with GMP standards. In the future, 3S Pharmaceutical Group will continue to uphold the concept of “Care for Life, Cherish Life, Create Life” to create a world's leading bio-pharmaceutical company in China.
New Hiring activity — 1 fresh signal just appeared.
The order this company entered each market — oldest to newest
Zhang Jinwei Joins HKBMIA Board
Sign up to see the full signal feed
How 3SBio Inc.'s international expansion compares to its competitors
3SBio Inc.YouBars show relative size across the companies compared.
Columns5| Company | Markets | New markets | Momentum | Activity | Expansion score |
|---|---|---|---|---|---|
 3SBio Inc.You | 1 | 0 | +100% | 1 | 8 |
转化医学总监
View postingShanghai, China · last mo.
投资者关系经理
View postingHong Kong, Hong Kong SAR · last mo.
Country Sales Manager -Philippines
View postingShanghai, China · 3mo ago
No active campaigns
Sign up to track this company and get alerted the moment something changes.
CStone Pharmaceuticals reported 2023 revenue of RMB463.8 million, with commercial revenue of RMB368.1 million. The company made progress in collaborations, pipeline development, and clinical trials.
3SBio's anti-TL1A antibody (SSGJ-627) receives clinical trial application approval, becoming China's first domestic anti-TL1A antibody to enter clinical trials.
3SBio reports 17.70% revenue growth and 139.15% net profit increase in 2024, with strong product performance and R&D advancements.
Unlock verified emails & direct dials
Free · No credit card needed
Quick answers about 3SBio Inc.'s business, markets, and growth signals.
Pubrio glocalizes business, people, and intent data from 50+ local sources into one global graph, giving AI and revenue teams full‑market visibility.
© 2026 Pubrio. All rights reserved.
